The study and treatment of dystonias in childhood;Estudio y tratamiento de las distonías en la infancia

Revista de Neurologia

Volumn 43, Issue SUPPL. 1, 2006, Pages

  Pascual Pascual, S I ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antidystonic drugs; Botulinum toxin type A; Childhood dystonias; Deep brain stimulation; Hereditary dystonias; Intratecal baclofen; Study and treatment

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; LEVODOPA; NEUROLEPTIC AGENT; NEUROTRANSMITTER; TETRABENAZINE; TIZANIDINE; TRIHEXYPHENIDYL;

BLURRED VISION; BRAIN DEPTH STIMULATION; CEREBRAL PALSY; CHILDHOOD; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DEGENERATIVE DISEASE; DYSTONIA; GENETIC COUNSELING; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; NAUSEA; PREVALENCE; SEDATION; SIDE EFFECT; SPASTICITY; TORSION DYSTONIA; URINARY FREQUENCY; URINE RETENTION; WEAKNESS; XEROSTOMIA;

EID: 35348861501     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.43s01.2006422     Document Type: Conference Paper

References (79)

1. Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW, Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111: e89-97.
2. Sanger TD. Toward a definition of childhood dystonia. Curr Opin Pediatr 2004; 16: 623-7.
3. Mink JW. The basal ganglia and involuntary movements. Arch Neurol 2003; 60: 1365-8.
4. Sanger TD. Childhood onset generalised dystonia can be modelled by increased gain in the indirect basal ganglia pathway. J Neurol Neurosurg Psychiatry 2003; 74: 1509-15.
5. Sanger TD. Pediatric movement disorders. Curr Opin Neurol 2003; 16: 529-35.
6. Kargo WJ, Nitz DA. Early skill learning is expressed through selection and tuning of cortically represented muscle synergies. J Neurosci 2003; 23: 11255-69.
7. Meunier S, Garnero L, Ducorps A, Mazieres L, Lehéricy, S, Tézenas du Montcel S, et al: Human brain mapping in dystonia reveals both endophenotypic traits and adaptive reorganization. Ann Neurol 2001; 50: 521-7.
8. Quartarone A, Bagnato S, Rizzo V, Siebner HR, Dattola V, Scalfari A, et al. Abnormal associative plasticity in the human motor cortex in writer's cramp. Brain 2003; 126: 2586-96.
9. Classen J. Focal hand dystonia: a disorder of neuroplasticity? Brain 2003; 126: 2571-2.
10. Berardelli A, Kaji R, Curra A. Physiology of dystonia. In Brin MF, Comella CL, Jankivic J, eds. Dystonia: etiology, clinical features and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 33-7.
11. Marsden CD. The pathophysiology of movement disorders. Neurol Clin 1984; 2: 435-59.
12. Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol 2004; 3: 673-8.
13. Fernández-Álvarez E. Frecuencia de los trastornos del movimiento en el niño. Rev Neurol 2001; 33: 228-9.
14. Kyllerman M, Bager B, Bensch J, Bille B, Olow I, Voss H. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidences. Acta Paediatr Scand 1982; 71: 543-50.
15. Kyllerman M. Dyskinetic cerebral palsy. II. Pathogenetic risk factors and intrauterine growth. Acta Paediatr Scand 1982; 71: 551-8.
16. Hagberg B, Hagberg G, Olow I, Von Wendt L. The changing panorama of cerebral palsy in Sweden. V. The birth year period 1979-82. Acta Paediatr Scand 1989; 78: 283-90.
17. Bressman SB, Taliati M, Klein C. Genetics of dystonia. In Brin MF, Comella CL, Jankivic J, eds. Dystonia: etiology, clinical features and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 11-21.
18. Fernández-Álvarez E, Aicardi J. Movement disorders with dystonia or athetosis as main clinical manifestation. In Fernández- Álvarez E, Aicardi J, eds. Movement disorders in children. London: Mac Keith Press/ICNA; 2001. p. 79-129.
19. García-Cazorla A, Ormazábal A, Artuch R, Pérez-Dueñas B, López-Casas J, Fernández- Álvarez E, et al. Errores congénitos de los neurotransmisores en neuropediatría. Rev Neurol 2005; 41: 99-108.
20. Pascual-Pascual SI. Apoyo de la neurofisiología en el diagnóstico de las enfermedades metabólicas. Rev Neurol 1999; 28: 24-32.
21. Williams D, Ford B, Fahn S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 1995; 65: 231-57.
22. Kirsch DB, Mink JW. Psychogenic movement disorders in children. Pediatr Neurol 2004; 30: 1-6.
23. Schrag A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2005; 18: 399-404.
24. Fernández-Álvarez E. Trastornos del movimiento de origen funcional (psicogénicos) en el niño. Rev Neurol 2005; 40 (Supl 1): S75-7.
25. Carvalho-Aguiar P, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol 2002; 1: 316-25.
26. Ozelius L, Kramer PL, Moskowitz CB, Kwiatkowski DJ, Brin MF, Bressman SB, et al. Human gene for torsion dystonia located on chromosome 9q32-34. Neuron 1989; 2: 1427-34.
27. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40-8.
28. Klein C, Liu L, Doheny D, Kock N, Muller B, Carvalho-Aguiar P, et al. Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol 2002; 52: 675-9.
29. Bressman SB, Heiman GA, Nygaard TG, Ozelius LJ, Hunt AL, Brin MF, et al. A study of idiopatic torsion dystonia in a non-Jewish family; evidence for a genetic heterogeneity. Neurology 1994; 44: 283-7.
30. Grundmann K, Laubis-Herrmann U, Bauer I, Dressler D, Vollmer-Haase J, Bauer P, et al. Frequency and phenotypic variability of the GAG delection of the DYT1 gene in an unselected group of patients with dystonia. Arch Neurol 2003; 60: 1266-70.
31. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14: 215-33.
32. Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994; 11: 236-40.
33. Uncini A, De Angelis MV, Di Fulvio P, Ragno M, Annesi G, Filla A, et al. Wide expressivity variation and high but no gender-related penetrance in two dopa-responsive dystonia families with a novel GCH-1 mutation. Mov Disord 2004; 19: 1139-45.
34. Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS, et al. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 1997; 48: 1290-7.
35. Hyland K, Arnold LA, Trugman JM. Defects of biopterin metabolism and biogenic amine byosinthesis. Clinical diagnostic and therapeutic aspects. Adv Neurol 1998; 78: 301-8.
36. Casseron W, Genton P. Dopa-sensitive dystonia-plus syndrome. Dev Med Child Neurol 2005; 47: 200-3.
37. Tsirikos AI, Carr LJ, Noordeen HH. Variability of clinical expression and evolution of spinal deformity in a family with late detection of dopa-responsive dystonia. Dev Med Child Neurol 2004; 46: 128-37.
38. Tassin J, Durr A, Bonnet AM, Gil R, Vidailhet M, Lucking CB, et al: Levodopa responsive dystonia: GTP cyclohydrolase I or parkin mutations? Brain 2000; 123: 1112-21.
39. Naumann M, Pirker W, Reiners K, Lange K, Becker G, Brucke T. (123)beta-CIT single photon emission tomography in dopa-responsive dystonia. Mov Disord 1997; 12: 448-51.
40. Head RA, De Goede CG, Newton RW, Walter JH, McShane MA, Brown RM, et al. Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Dev Med Child Neurol 2004; 46: 710-2.
41. Neubauer D, Frelih J, Zupancic N, Kopac S, Cindro-Heberle L. Pyruvate dehydrogenase deficiency presenting as dystonia and responding to levodopa. Dev Med Child Neurol; 2005; 47: 504.
42. Muller B, Hedrich K, Kock N, Dragasevic N, Svetel M, Garrels J, et al. Evidence that paternal expression of the epsilon-sarcoglycan gene accounts for reduced penetrance in myoclonus-dystonia. Am J Hum Genet 2002; 71: 1303-11.
43. Asmus F, Zimprich A, Tezenas du Montcel S, Kabus C, Deuschl G, Kupsch A, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489-92.
44. Nygaard TG, Raymond D, Chen C, Nishino I, Greene PE, Jennings D, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol 1999; 46: 794-8.
45. Marechal L, Raux G, Dumanchin C, Lefebvre G, Deslandre E, Girard C, et al. Severe myoclonus-dystonia syndrome associated with a novel epsilon-sarcoglycan gene truncation mutation. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 114-7.
46. Grundmann K, Laubis-Herrmann U, Dressler D, Vollmer-Haase J, Bauer P, Stuhrmann M, et al. Lack of mutations in the epsilon-sarcoglycan gene in patients with different subtypes of primary dystonias. Mov Disord 2004; 19: 1294-7.
47. Grimes DA, Han F, Lang AE, St George-Hyssop P, Racacho L, Bulman DE. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 2002; 59: 1183-6.
48. Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, et al. Rapid-onset dystonia-parkinsonism. Neurology 1993; 43: 2596-602.
49. Kramer PL, Mineta M, Klein C, Schilling K, De Leon D, Farlow MR, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol 1999; 46: 176-82.
50. Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 2004; (Suppl 144): S3-14.
51. Roze E, Paschke E, López N, Eck T, Yoshida K, Maurel-Ollivier A, et al. Dystonia and Parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005, 20: 1366-9.
52. Gray DB, Hendershot GE. The ICIDH-2: developments for a new era of outcomes research. Arch Phys Med Rehabil 2000; 81 (Suppl 2): S10-4.
53. Lollar DJ, Simeonsson RJ, Nanda U. Measures of outcomes for children and youth. Arch Phys Med Rehabil 2000; (Suppl 81): S46-52.
54. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73-7.
55. Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T, Dystonia Study Group. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003; 18: 303-12.
56. Byl N. Nonpharmacologic therapies. In Brin MF, Comella CL, Jankivic J, eds. Dystonia: etiology, clinical features and treatment. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 41-63
57. Segawa M, Nishiyama N, Nomura Y. Dopa-responsive dystonic parkinsonism: pathophysiologic considerations. Adv Neurol 1999; 80: 389-400.
58. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol 1988; 50: 377-84.
59. Greene P, Sable H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46-60.
60. Greene P, Sable H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988; 50: 547-56.
61. Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984; 47: 1166-73.
62. Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol 1983; 37: 189-92.
63. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36: 160-4.
64. Hoon Jr. AH, Freese PO, Reinhardt EM, Wilson MA, Lawrie Jr. WT, Harryman SE, et al. Age-dependent effects of trihexyphenidyl in extrapyramidal cerebral palsy. Pediatr Neurol 2001; 25: 55-8.
65. Greene PE, Fahn S. Baclofen in the treatment of idiopatic dystonia in children. Mov Disord 1992; 7: 48-52.
66. Albright AL, Barry MJ, Shafton DH, Ferson SS. Intratecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43: 652-7.
67. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994; 4 (Suppl 9): S6-10.
68. Lang AE, Riley DE. Tizanidine in cranial dystonia. Clin Neuropharmacol 1992; 15: 142-7.
69. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine. A double-blind crossover study. Ann Neurol 1982; 11: 41-7.
70. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358-62.
71. Heggarty H, Wright T. Tetrabenazine in athetoid cerebral palsy. Dev Med Child Neurol 1974; 16: 137-42.
72. Brin M. Botulinum toxin: chemistry, pharmacology, toxicity and inmunology. Muscle Nerve 1997; (Suppl 6): S146-68.
73. Brin MF, Aoki KR. Botulinum toxin type A: pharmacology. In Mayer NH, Simpson DM, eds. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York:We Move; 2002. p. 110-24.
74. Jankovic J. Treatment of dystonia. In Watts RL, Koller WC, eds. Movement disorders: neurologic principles and practice. New York: McGraw-Hill; 1997. p. 443-54.
75. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990; 53: 633-9.
76. Brans JW, Lindeboom R, Snoek JW, Zwarts MJ, Van Weerden TW, Brunt ER, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46: 1066-72.
77. Vitek JL. Mechanisms of deep brain stimulation: excitation or inhibition. Mov Disord 2002; 17 (Suppl 3): S69-72.
78. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalized dystonia by stimulation of the internal globus pallidus. Lancet 2000; 355: 2220-1.
79. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Benabid AL, Cornu P, et al. French Stimulation du Pallidum Interne dans la Dystonie (SPIDY) Study Group. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352: 459-68.